Abbruch

The Gynmed Team is highly engaged in further improving the laws and regulations on contraception and abortion as well as the care and medical treatment of women. To this goal we publish new insights and findings. Following please find a list of articles from medical journals written or co-authored by members of the team. The publications are in English and German.

Abortion: legislation and statistics in Europe

The European Journal of Contraception & Reproductive Health Care, Christian Fiala, Aubert Agostini, Teresa Bombas, Roberto Lertxundi, Marek Lubusky, Mirella Parachini & Kristina Gemzell-Danielsson, 14. 4月 2022
リンク
Experiences of Women Accessing an Abortion Clinic Confronted by Religiously Motivated Demonstrators: A Pilot Study

PubMed, Christian Fiala, Johanna Özogul, Jennifer Kernreiter, 21. 4月 2020
リンク
Management of Very Early Medical abortion - An International Survey Among Providers

PubMed, Christian Fiala, Teresa Bombas, Mirella Parachini, Aubert Agostini, Roberto Lertxundi, Marek Lubusky, Laurence Saya, Kristina Gemzell Danielsson, 01. 2月 2020
リンク
Management of Pain Associated With up-to-9-weeks Medical Termination of Pregnancy (MToP) Using Mifepristone-Misoprostol Regimens: Expert Consensus Based on a Systematic Literature Review

PubMed, C Fiala, A Agostini, T Bombas, S Cameron, R Lertxundi, M Lubusky, M Parachini, L Saya, B Trumbic, K Gemzell Danielsson, 03. 9月 2019
リンク
Outcome of first trimester medical termination of pregnancy: definitions and management

Christian Fiala, Sharon Cameron, Teresa Bombas, Mirella Parachini, Aubert Agostini, Roberto Lertxundi, Marek Lubusky, Laurence Saya & Kristina Gemzell Danielsson, 02. 1月 2019
Pdf , 2.02 MB リンク
hCG Testing to Determine Outcome after Medical Abortion: A Review

J Preg Child Health , Christian Fiala, Teresa Bombas, Mirella Parachini, Aubert Agostini, Roberto Lertxundi, Marek Lubusky and Kristina Gemzell Danielsson, 2019
Pdf , 679.21 KB リンク
Early Medical Abortion - A Practical Guide For Healthcare Professionals

Editions de Santé, Dr Christian FIALA, Pr Aubert AGOSTINI, Dr Teresa-Alexandra CARMO-BOMBAS, Pr Kristina GEMZELL-DANIELSSON, Dr Roberto LERTXUNDI, Pr Marek LUBUSKY, Dr Mirella PARACHINI, 2018
Pdf , 1.47 MB
Pain management for up to 9 weeks medical abortion - An international survey among abortion providers.

Eur J Obstet Gynecol Reprod Biol. , Fiala C, Cameron S, Bombas T, Parachini M, Agostini A, Lertxundi R, Gemzell-Danielsson K., 2018
Pdf , 92.23 KB リンク
Efficacy and safety of very early medical termination of pregnancy: a cohort study.

PubMed, Bizjak I, Fiala C, Berggren L, Hognert H, Sääv I, Bring J, Gemzell-Danielsson K, 27. 9月 2017
リンク
There is no defense for ‘Conscientious objection’ in reproductive health care

Christian Fiala, Joyce H. Arthur, 7月 2017
Pdf , 510.53 KB リンク
Assessment of pain during medical abortion with home use of misoprostol.

PubMed, Cavet S, Fiala C, Scemama A, Partouche H, 22. 6月 2017
リンク
The dishonourable disobedience of not providing abortion.

PubMed, Arthur J, Fiala C, Gemzell Danielsson K, Heikinheimo O, Guðmundsson JA, 22. 2月 2017
リンク
Routine misoprostol before all surgical abortions.

PubMed, Cameron S, Fiala C, Gemzell-Danielsson K, 11月 2016
リンク
Yes we can! Successful examples of disallowing 'conscientious objection' in reproductive health care.

Fiala C, Gemzell Danielsson K, Heikinheimo O, Guðmundsson JA, Arthur J., 03. 2月 2016
Pdf , 750.07 KB
Medical Abortion beyond the 1st trimester

Editions de Santé, Kristina GEMZELL-DANIELSSON, Christian FIALA,  Aubert AGOSTINI,  Sharon CAMERON, Teresa BOMBAS, Roberto LERTXUNDI, Marek LUBUSKY, Mirella PARACHINI, 2016
Pdf , 6.68 MB
Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial.

PubMed, Oppegaard KS, Qvigstad E, Fiala C, Heikinheimo O, Benson L, Gemzell-Danielsson K, 21. 2月 2015
リンク
Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: a double-blinded RCT  

Human Reproduction, Ingrid Saav; Helena Kopp Kallner; Christian Fiala; Kristina Gemzell-Danielsson, 2015
リンク
Instability of misoprostol tablets stored outside the blister: a potential serious concern for clinical outcome in medical abortion.

PubMed, Berard V, Fiala C, Cameron S, Bombas T, Parachini M, Gemzell-Danielsson K, 15. 12月 2014
リンク
Pain during medical abortion, the impact of the regimen: a neglected issue? A review.

PubMed, Fiala C, Cameron S, Bombas T, Parachini M, Saya L, Gemzell-Danielsson K., 12月 2014
リンク
Why We Need to Ban ‘Conscientious Objection’ in Reproductive Health Care

Joyce Arthur, Abortion Rights Coalition of Canada and Christian Fiala, Gynmed Clinic for Abortion and Family Planning, 14. 5月 2014
リンク
“Dishonourable disobedience” – Why refusal to treat in reproductive healthcare is not conscientious objection

Christian Fiala, Joyce H. Arthur, 3月 2014
リンク
Conscientious objection and induced abortion in Europe.

Eur J Contracept Reprod Health Care, Heino A, Gissler M, Apter D, Fiala C., 8月 2013
リンク
Is the introduction of anonymous delivery associated with a reduction of high neonaticide rates in Austria?

BJOG, Klier CM, Grylli C, Amon S, Fiala C, Weizmann-Henelius G, Pruitt SL, Putkonen H., 05. 12月 2012
リンク
Assessment of significant factors affecting acceptability of home administration of misoprostol for medical abortion

Contraception, Kopp Kallner H, Fiala C, Gemzell-Danielsson K., 85(4):394-7., 4月 2012
リンク
Effect of bacterial vaginosis on the pharmacokinetics of misoprostol in early pregnancy.

Hum Reprod., Sioutas A, Sandström A, Fiala C, Watzer B, Schweer H, Gemzell-Danielsson K., 2月 2012
リンク
Medical abortion in lactating women - low levels of mifepristone in breast milk

Acta Obstet Gynecol Scand., Sääv I, Fiala C,Hämäläinen JM, Heikinheimo O, Gemzell-Danielsson K., 89(5):618-22, 5月 2010
リンク
Home self administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days

Hum Reprod., Kopp Kallner H, Fiala C, Stephansson O, Gemzell-Danielsson K., 25(5):1153-7, 5月 2010
リンク
Providing Medical Abortion in Low-Resource Settings

Gynuity, 2009
Pdf , 88.55 KB
Evaluation of Early Medical Abortion (EMA) Pilot Sites

University of Southampton and Department of Health, London , Roger Ingham and Ellie Lee et al., 07. 5月 2008
リンク
Cervical priming with misoprostol prior to transcervical procedures

Int J Gynaecol Obstet., Fiala C, Gemzell-Danielsson K., Tang OS, von Hertzen H, 99 Suppl 2:S168-71, 12月 2007
リンク
Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy

Int J Gynaecol Obstet., Faundes A, Fiala C, Tang OS, Velasco A., 99 Suppl 2:S172-7, 12月 2007
リンク
Misoprostol for intrauterine fetal death

Int J Gynaecol Obstet., Gómez Ponce de León R, Wing D, Fiala C, 99 Suppl 2:S190-3, 12月 2007
リンク
Misoprostol: first-line therapy for incomplete miscarriage in the developing world

BJOG, Gemzell-Danielsson K, Fiala C, Weeks A., 114(11):1337-9, 11月 2007
リンク
Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol

Hum Reprod., Aronsson A, Fiala C, Stephansson O, Granath F, Watzer B, Schweer H, Gemzell-Danielsson K., 22(7):1912-8, 7月 2007
リンク
Restricting access to safe abortion poses a serious health risk for women

ESC newsletter, ESC, European Society of Contraception: Expert Group on abortion - C. Fiala, Austria and C. Gemzell, Sweden, 6月 2007
Pdf , 438.62 KB
Review of medical abortion using mifepristone in combination with a prostaglandin analogue

Contraception, Fiala C, Gemzel-Danielsson K., 74(1):66-86, 7月 2006
リンク
Frequently asked clinical questions about medical abortion

WHO, 2006
Pdf , 200 KB リンク
Pharmacokinetics of a novel oral slow-release form of misoprostol

Hum Reproduction, Fiala C, Aronsson A, Granath F, Stephansson O, Seyberth HW, Watzer B, Gemzell-Danielsson K., 20(12):3414-8, 12月 2005
リンク
The effect of non-steroidal anti-inflammatory drugs (NSAIDs) on medical abortion with mifepristone and misoprostol at 13 to 22 weeks gestation

Human Reproduction, C. Fiala, ML. Swahn, O. Stephansson, and K. Gemzell-Danielsson, 20(11):3072-7, 11月 2005
リンク
Effects of slow release misoprostol on uterine contractility in early pregnancy

Human Reproduction, C. Fiala, A. Aronsson, O. Stephansson and K. Gemzell-Danielsson, 20(9):2648-52., 9月 2005
リンク
Abortion in Europe: Are the Laws and Practices patient centered?

Entre Nous magazine, UNFPA/ WHO No. 59, Christian Fiala, 23/5, 2005
Pdf , 28.86 KB
Acceptability of home-use of misoprostol in medical abortion

Contraception, Fiala C, Winikoff B, Helstrom L, Hellborg M, Gemzell-Danielsson K., 70(5):387-92., 11月 2004
リンク
Rh-prophylaxis in early abortion

Acta Obstet Gynecol Scand., Fiala C, Fux M, Gemzell Danielsson K., 82(10):892-903. Review, 10月 2003
リンク
Verifying the effectiveness of medical abortion; ultrasound versus hCG testing

Eur J Obstet Gynecol Reprod Biology, Fiala C, Safar P, Bygdeman M, Gemzell-Danielsson K., 109(2):190-5., 15. 8月 2003
リンク
Medical abortion - where we are in Europe

Entre Nous magazine, UNFPA/ WHO No 47-48, Christian Fiala, 16-17, 9月 2000

Abortion: legislation and statistics in Europe

Experiences of Women Accessing an Abortion Clinic Confronted by Religiously Motivated Demonstrators: A Pilot Study

Management of Very Early Medical abortion - An International Survey Among Providers

Management of Pain Associated With up-to-9-weeks Medical Termination of Pregnancy (MToP) Using Mifepristone-Misoprostol Regimens: Expert Consensus Based on a Systematic Literature Review

Outcome of first trimester medical termination of pregnancy: definitions and management

hCG Testing to Determine Outcome after Medical Abortion: A Review

Early Medical Abortion - A Practical Guide For Healthcare Professionals

Pain management for up to 9 weeks medical abortion - An international survey among abortion providers.

Efficacy and safety of very early medical termination of pregnancy: a cohort study.

There is no defense for ‘Conscientious objection’ in reproductive health care

Assessment of pain during medical abortion with home use of misoprostol.

The dishonourable disobedience of not providing abortion.

Routine misoprostol before all surgical abortions.

Yes we can! Successful examples of disallowing 'conscientious objection' in reproductive health care.

Medical Abortion beyond the 1st trimester

Clinical follow-up compared with self-assessment of outcome after medical abortion: a multicentre, non-inferiority, randomised, controlled trial.

Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: a double-blinded RCT

Instability of misoprostol tablets stored outside the blister: a potential serious concern for clinical outcome in medical abortion.

Pain during medical abortion, the impact of the regimen: a neglected issue? A review.

Why We Need to Ban ‘Conscientious Objection’ in Reproductive Health Care

“Dishonourable disobedience” – Why refusal to treat in reproductive healthcare is not conscientious objection

Conscientious objection and induced abortion in Europe.

Is the introduction of anonymous delivery associated with a reduction of high neonaticide rates in Austria?

Assessment of significant factors affecting acceptability of home administration of misoprostol for medical abortion

Effect of bacterial vaginosis on the pharmacokinetics of misoprostol in early pregnancy.

Medical abortion in lactating women - low levels of mifepristone in breast milk

Home self administration of vaginal misoprostol for medical abortion at 50-63 days compared with gestation of below 50 days

Providing Medical Abortion in Low-Resource Settings

Evaluation of Early Medical Abortion (EMA) Pilot Sites

Cervical priming with misoprostol prior to transcervical procedures

Misoprostol for the termination of pregnancy up to 12 completed weeks of pregnancy

Misoprostol for intrauterine fetal death

Misoprostol: first-line therapy for incomplete miscarriage in the developing world

Pharmacokinetic profiles up to 12 h after administration of vaginal, sublingual and slow-release oral misoprostol

Restricting access to safe abortion poses a serious health risk for women

Review of medical abortion using mifepristone in combination with a prostaglandin analogue

Frequently asked clinical questions about medical abortion

Pharmacokinetics of a novel oral slow-release form of misoprostol

The effect of non-steroidal anti-inflammatory drugs (NSAIDs) on medical abortion with mifepristone and misoprostol at 13 to 22 weeks gestation

Effects of slow release misoprostol on uterine contractility in early pregnancy

Abortion in Europe: Are the Laws and Practices patient centered?

Acceptability of home-use of misoprostol in medical abortion

Rh-prophylaxis in early abortion

Verifying the effectiveness of medical abortion; ultrasound versus hCG testing

Medical abortion - where we are in Europe

Sublingual versus vaginal misoprostol for cervical dilatation 1 or 3 h prior to surgical abortion: a double-blinded RCT  